-
Sulfaphenazole as a Causal CYP2C9 Probe
2026-09-17
Sulfaphenazole is more than a CYP2C9 inhibitor: it is a useful causal probe for connecting cytochrome P450 activity with oxidative stress and endothelial dysfunction. This guide translates the key vascular study into practical assay decisions while separating CYP biology from its antibacterial DHPS activity.
-
Ziprasidone Hydrochloride: Assay Guide
2026-09-17
This scenario-based guide explains how Ziprasidone Hydrochloride (SKU A5350) can support reproducible cell viability, proliferation, cytotoxicity, and permeability workflows. It connects concentration selection, solvent control, mechanism-aware interpretation, and practical vendor evaluation to published quantitative evidence.
-
MTSEA-biotin for Cysteine Accessibility Assays
2026-09-17
MTSEA-biotin converts solvent-exposed cysteines into a biotin-based readout for membrane proteins, purified complexes, and engineered accessibility assays. This guide connects practical thiol-labeling workflows with the reference study’s site-resolved view of regulatory biology while clearly separating direct evidence from assay extensions.
-
Recombinant Human IL-6, Tag Free for Embryo Studies
2026-09-16
Recombinant Human IL-6, Tag Free provides a defined cytokine perturbation for dissecting signaling and metabolic phenotypes in human blastoid research. This article explains how to use IL-6 as an orthogonal assay variable without confusing it with the WDR36–glycolysis mechanism established in the reference study.
-
MK-8745: A Selective Aurora A Inhibitor
2026-09-15
MK-8745 provides a practical way to connect Aurora A inhibition with mitotic arrest, tetraploidy, and apoptosis across cancer models. Its high biochemical potency, selectivity, and compatibility with cell-cycle, p53, lymphoma, and xenograft workflows make it useful for mechanism-led oncology research.
-
EZ Cap™ Human PTEN mRNA: Assay Design
2026-09-15
Explore how EZ Cap™ Human PTEN mRNA supports mechanism-driven cancer research through Cap 1 translation, poly(A)-tail stability, and controlled PTEN restoration. This guide also interprets a transdermal HA-LNP melanoma study to improve delivery comparisons and assay decisions.
-
KDM4D, Foxo1, and MSC Quiescence in Iron Deficiency
2026-09-14
The reference study identifies an iron-sensitive KDM4D–H3K9me3–PIK3R3 regulatory route that controls mesenchymal stem cell activation through PI3K-Akt-Foxo1 signaling. Its findings connect iron deficiency with impaired bone marrow MSC mobilization and reduced bone mass, while suggesting that pathway-level intervention can mitigate this phenotype.
-
Leucomycin In Vitro Antibacterial Activity Study
2026-09-14
Iwata and Akiba’s 1962 study established a systematic in vitro profile of Leucomycin, including its A1 fraction, across clinically relevant bacterial groups and antibiotic-resistant staphylococci. Its comparative design remains useful for interpreting component activity, medium effects, and susceptibility workflows in modern macrolide resistance characterization.
-
Sunitinib Workflows for RTK and Angiogenesis Research
2026-09-13
Build reproducible Sunitinib assays for RTK signaling, tumor angiogenesis, apoptosis, and ATRX-linked drug sensitivity. This guide connects practical dosing and troubleshooting with renal cell carcinoma, nasopharyngeal carcinoma, and high-grade glioma research use cases.
-
AZD6482: A Context-Aware PI3Kβ Research Guide
2026-09-12
Explore AZD6482 as a selective PI3Kβ inhibitor through a context-aware framework linking target engagement, platelet biology, metabolic assays, and RNA-foci study design. Learn how to interpret its selectivity without conflating PI3Kβ signaling with HSP90-dependent regulation in DM1.
-
Ibotenic Acid: Workflows for NMDA Research
2026-09-12
Build more informative glutamatergic assays with Ibotenic acid, combining receptor-driven activity changes with behavioral, biochemical, c-fos, and Nissl readouts. This practical guide distinguishes formulation controls from literature-based toxicity observations so the compound can be deployed as a neuroscience research tool with clearer interpretation and better reproducibility.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-09-11
A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive inhibitor of GOT1, linking a known antipsychotic scaffold to glutamine-metabolism disruption in pancreatic ductal adenocarcinoma. Its combination of biochemical, metabolomic, cellular, genetic, and xenograft evidence supports GOT1 as a mechanistically relevant vulnerability, while also highlighting the substantial work needed before clinical translation.
-
Triiodothyronine and Adipose Thermogenesis
2026-09-11
Triiodothyronine (T3) provides a receptor-level way to interrogate adipose thermogenesis. This article connects T3 assay design with SETD7-dependent white adipose browning while separating established evidence from testable metabolic hypotheses.
-
Phytol Workflows for RXR Assays and Nanomaterials
2026-09-10
Phytol is a practical probe for retinoid X receptor signaling, but its insolubility, isomeric composition, and GABAergic activity demand disciplined assay design. This guide combines concentration-control workflows with lessons from shaped coil-bottlebrush self-assembly research to improve reproducibility in receptor, cell, and exploratory materials studies.
-
Gepotidacin for Uncomplicated Urogenital Gonorrhea
2026-09-10
This phase 2 randomized study evaluated whether a single oral dose of gepotidacin could eradicate uncomplicated urogenital Neisseria gonorrhoeae infection. Both 1500-mg and 3000-mg doses produced high microbiological cure rates, while treatment failures were associated with a shared bacterial mutation and the highest observed gepotidacin MIC.